HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients.

Abstract
The clinical importance of routine drug monitoring of serum concentrations of morphine, morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) during chronic morphine therapy is not established. We measured morphine, M6G and M3G serum concentrations in cancer pain patients receiving oral (n = 263, median dose 80 mg/24 hours) or subcutaneous (sc) (n = 35, median dose 110 mg/24 hours) morphine. Regression analyses were performed to investigate if serum concentrations of morphine, M3G and M6G predicted pain intensity (Brief Pain Inventory), health-related quality-of-life variables (EORTC QLQ-C30) and cognitive function (Mini-Mental Score). Serum concentrations were also compared in patients categorized as morphine 'treatment successes' and 'treatment failures'. We observed that serum concentrations of morphine, M6G or M3G did not predict pain intensity, cognitive function, nausea or tiredness. 'Treatment failures' caused by nausea, tiredness, cognitive failure or constipation did not have statistically significant different morphine, M6G and M3G serum concentrations than patients classified as 'treatment successes'. In conclusion, this study did not observe any concentration-effect relationships of morphine, M3G or M6G with pain intensity, nausea, constipation, tiredness or cognitive failure in blood samples obtained during routine clinical drug monitoring in cancer patients. This result suggests that therapeutic drug monitoring as a routine tool during chronic morphine treatment has limited value for clinical decision making.
AuthorsPål Klepstad, Petter C Borchgrevink, Ola Dale, Kolbjørn Zahlsen, Trond Aamo, Peter Fayers, Bjørn Fougner, Stein Kaasa
JournalPalliative medicine (Palliat Med) Vol. 17 Issue 8 Pg. 679-87 (Dec 2003) ISSN: 0269-2163 [Print] England
PMID14694919 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Analgesics, Opioid
  • Morphine Derivatives
  • morphine-6-glucuronide
  • Morphine
  • morphine-3-glucuronide
Topics
  • Administration, Oral
  • Adult
  • Aged
  • Aged, 80 and over
  • Analgesics, Opioid (administration & dosage, blood)
  • Cognition Disorders (chemically induced)
  • Dose-Response Relationship, Drug
  • Drug Monitoring
  • Fatigue (chemically induced)
  • Female
  • Humans
  • Infusions, Parenteral
  • Male
  • Middle Aged
  • Morphine (administration & dosage, blood)
  • Morphine Derivatives (blood)
  • Nausea (chemically induced)
  • Neoplasms (blood, complications)
  • Pain (blood, prevention & control)
  • Pain Measurement
  • Palliative Care

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: